Akums Drugs & Pharmaceuticals Ltd Stock Price Today (NSE: AKUMS)
Fundamental Score
Akums Drugs & Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Akums Drugs & Pharmaceuticals Ltd share price today is ₹531.25, up +1.26% on NSE/BSE as of 19 June 2026. Akums Drugs & Pharmaceuticals Ltd (AKUMS) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹6.70K (Cr). The 52-week high for AKUMS share price is ₹597.00 and the 52-week low is ₹409.30. At a P/E ratio of 21.76x, AKUMS is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 17.19% and a debt-to-equity ratio of 0.03.
Akums Drugs & Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Akums Drugs & Pharmaceuticals Ltd share price chart: 0.69% return over the past month. 52-week high ₹597.00, 52-week low ₹409.30.
Akums Drugs & Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹520.95 | ₹533.40 | ₹517.00 | ₹531.25 | 88.38K (Cr) | |
| ₹524.50 | ₹543.90 | ₹523.20 | ₹524.65 | 1.72L (Cr) | |
| ₹537.90 | ₹543.00 | ₹522.00 | ₹524.50 | 84.91K (Cr) | |
| ₹535.05 | ₹548.50 | ₹535.00 | ₹535.25 | 2.18L (Cr) | |
| ₹521.60 | ₹551.60 | ₹521.60 | ₹532.20 | 3.02L (Cr) | |
| ₹530.00 | ₹531.85 | ₹514.90 | ₹521.00 | 1.19L (Cr) | |
| ₹523.50 | ₹525.45 | ₹516.60 | ₹520.05 | 2.22L (Cr) | |
| ₹516.00 | ₹527.40 | ₹509.15 | ₹521.35 | 2.21L (Cr) | |
| ₹516.00 | ₹523.65 | ₹510.35 | ₹514.95 | 3.22L (Cr) | |
| ₹519.75 | ₹530.90 | ₹517.95 | ₹519.80 | 3.01L (Cr) |
Akums Drugs & Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹524.50 | ₹543.90 | ₹517.00 | ₹531.25 | +1.29% | |
| ₹550.00 | ₹567.00 | ₹500.05 | ₹524.50 | -4.64% | |
| ₹473.90 | ₹557.00 | ₹473.90 | ₹547.30 | +15.49% | |
| ₹472.00 | ₹515.00 | ₹456.55 | ₹466.10 | -1.25% | |
| ₹445.00 | ₹506.00 | ₹424.20 | ₹488.15 | +9.70% | |
| ₹453.40 | ₹458.00 | ₹409.30 | ₹439.55 | -3.05% | |
| ₹425.95 | ₹480.50 | ₹414.00 | ₹453.40 | +6.44% | |
| ₹463.95 | ₹481.70 | ₹411.40 | ₹425.95 | -8.19% | |
| ₹441.50 | ₹473.45 | ₹437.00 | ₹460.75 | +4.36% | |
| ₹456.00 | ₹484.00 | ₹438.05 | ₹441.45 | -3.19% | |
| ₹520.00 | ₹524.85 | ₹452.20 | ₹454.25 | -12.64% | |
| ₹588.50 | ₹592.00 | ₹511.70 | ₹519.25 | -11.77% |
AI Research Briefing
Powered by Gemini · 2026-04-17
CDMO play with EU optionality; execution is everything.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Akums Drugs shows bullish momentum with positive daily moving averages. 84% increase from the previous close. ICICI Securities upgraded the stock to 'Hold' on April 10, 2026. FII holding increased to 1.38% in March 2026 from 1.14% in December 2025. Akums closed its trading window on April 1, 2026, in anticipation of FY26 results.
CORE STORY (THE REAL GAME)
Akums is being priced as a CDMO play, leveraging its manufacturing capabilities for regulated markets. The key is its ability to secure and execute long-term contracts with global pharma companies, shifting from generics to higher-margin formulations.
- Bullish technical indicators signal upward price momentum
- FIIs increased stake in Q4 FY26
- EU GMP certifications received, paving the way for regulated market access
- New CDMO contract wins
- Successful commencement of European supplies in FY28
- Faster-than-expected ramp-up of Zambia JV
- Small-cap, inherent liquidity risk
- Q2 PAT decline raises concerns about CDMO growth sustainability
- Revenue concentration risk from reliance on large contracts
FII increased stake from 1.14% to 1.38% in Q4 FY26
Indian pharma sector shifting towards backward integration and innovation.
Akums has a ₹1,760 Cr contract with a European pharma company for oral liquid formulations, with commercial supply expected from 2027.
Profit converting to cash. Free Cash Flow 5Y: ₹132.48 Cr
Focus on executing existing contracts and securing new ones in regulated markets. European expansion is key to margin expansion over the next 2-3 years.
Primary Thesis Risk
Failure to execute on EU expansion will decimate the multiple.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Akums Drugs & Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Akums Drugs & Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AKUMS across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (17.19%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (16.20%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 21.76 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Profit Growth Track Record (48.93% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.03)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (6.61x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹132.48 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Profit Decline Concern (-34.83%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (-42.93% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Akums Drugs & Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Akums Drugs & Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
46.1/100 | ₹531.25₹531 | ₹6697.10₹6697.10 | 21.76Average 21.8 Average | 17.19%Good 17.19% Good | 16.20%Good 16.20% Good | 0.03Excellent 0.0 Excellent | 48.93%Excellent 48.93% Excellent | 11.27%Good 11.27% Good | 0.00% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Akums Drugs & Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for AKUMS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹22.60 | ₹453.40 | 20.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Akums Drugs & Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for AKUMS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-1.51%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-34.83%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
11.27%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
48.93%
Compounded annual net profit growth over 5 years
Akums Drugs & Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AKUMS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Akums Drugs & Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Akums Drugs & Pharmaceuticals Ltd (AKUMS) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Akums Drugs & Pharmaceuticals Ltd
About AKUMS (Akums Drugs & Pharmaceuticals Ltd)
Akums Drugs & Pharmaceuticals Ltd. is a powerhouse within the Indian pharmaceutical landscape, standing as a comprehensive contract development and manufacturing organization (CDMO...). They function as a vital hub, orchestrating the production of a vast portfolio of pharmaceutical and healthcare solutions, spanning from essential medications to sophisticated formulations. The company's expertise extends across diverse therapeutic areas, catering to both acute and chronic conditions with unwavering commitment to quality and innovation. With a strong foothold in the domestic market, Akums also strategically projects its reach globally, solidifying its position as a reliable partner for pharmaceutical companies seeking manufacturing excellence. This unwavering dedication has positioned Akums as a significant contributor to the healthcare industry, enabling the provision of affordable and quality healthcare solutions for diverse demographics. Beyond conventional pharmaceuticals, Akums embraces a holistic approach to well-being, demonstrated by its involvement in the production of ayurvedic medicines, herbal remedies, and nutraceuticals. This reflects an awareness of the growing consumer demand for natural and alternative therapies, with production conducted under rigorous regulatory standards and quality controls. The company's comprehensive product range further incorporates toiletries, derma and cosmetic products, and food supplements, showcasing its diversification and commitment to addressing various aspects of health and personal care. Akums is dedicated to continuously refining its processes and technologies, ensuring the delivery of products that align with the evolving needs of the healthcare industry. Akums Drugs & Pharmaceuticals Ltd. operates a network of state-of-the-art manufacturing facilities adhering to stringent international quality standards, including certifications from WHO-GMP and other reputed regulatory bodies. This infrastructural strength enables the company to deliver a wide range of dosage forms, including tablets, capsules, liquids, injectables, and topical preparations. Moreover, the company offers a comprehensive suite of services encompassing formulation development, analytical testing, and stability studies, positioning it as a complete solution provider for pharmaceutical companies. By fostering collaborations and partnerships, Akums aims to drive advancements in healthcare, enabling access to quality and affordable medicines for populations worldwide.
Company Details
Key Leadership
Latest News
AKUMS Share Price: Frequently Asked Questions
What is the current share price of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd (AKUMS) trades at ₹531.25 on NSE and BSE. Market cap ₹6.70K (Cr). Educational data only.
What is the P/E ratio of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd has a P/E of 21.76x vs industry average 31.77x.
What is the Bull Run score for Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd has a Bull Run score of 46.1/100 based on 25+ financial parameters.
Does Akums Drugs & Pharmaceuticals Ltd pay dividends?
Akums Drugs & Pharmaceuticals Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd has ROE of 17.19%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd has debt-to-equity of 0.03.
Is Akums Drugs & Pharmaceuticals Ltd a good investment?
Bull Run gives Akums Drugs & Pharmaceuticals Ltd a score of 46.1/100. This is not investment advice — consult a SEBI-registered advisor.